Biodesix (BDSX) Stock Price, News & Analysis

Company Overview

Biodesix, Inc. is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of cancer, with an emphasis on lung disease. The company combines blood-based testing, data science and artificial intelligence to help physicians assess cancer risk, guide treatment decisions and monitor patients.

Biodesix’s portfolio includes diagnostic tests for lung nodules and lung cancer, including the Nodify Lung Nodule Risk Assessment suite and blood-based assays such as GeneStrat and VeriStrat. These products are designed to support the evaluation of suspicious lung nodules, identify molecular characteristics of tumors and help inform therapy selection and patient management.

The company serves healthcare providers, health systems, laboratories and biopharmaceutical companies, primarily in the United States. Its offerings are used in clinical care as well as in pharmaceutical development and research. Biodesix was founded in 2005 and became a publicly traded company on the Nasdaq in 2021.

Key Stats

• Today's Range: $26.07 to $27.78
• 50-Day Range: $21.20 to $30.60
• 52-Week Range: $5.26 to $31.97
• Volume: 57,569 shs
• Average Volume: 104,204 shs
• Market Capitalization: $278.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Moderate Buy

Biodesix Stock Analysis - MarketRank™

Biodesix scored higher than 83% of companies evaluated by MarketBeat, and ranked 80th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biodesix has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Biodesix has a consensus price target of $35.00, representing about 32.5% upside from its current price of $26.42.

Amount of Analyst Coverage

Biodesix has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biodesix are expected to grow in the coming year, from ($2.68) to ($1.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biodesix is -8.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biodesix is -8.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.64% of the float of Biodesix has been sold short.

Short Interest Ratio / Days to Cover

Biodesix has a short interest ratio ("days to cover") of 3.29, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodesix has recently decreased by 2.89%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biodesix does not currently pay a dividend.

Dividend Growth

Biodesix does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.26

News Sentiment

Biodesix has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Biodesix this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Biodesix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $1,033,062.00 in company stock, which represents 0.3706% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Biodesix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,033,062.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

23.20% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

20.96% of the stock of Biodesix is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/07/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:BDSX
• CIK: 1439725
• Web: www.biodesix.com
• Phone: 303-417-0500
• Fax: N/A
• Employees: 334
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Biodesix: $35.00
• High Price Target: $38.00
• Low Price Target: $32.00
• Potential Upside/Downside: +32.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.26 million
• Net Margins: -26.97%
• Pretax Margin: -26.97%
• Return on Equity: -788.19%
• Return on Assets: -30.33%

Debt

• Debt-to-Equity Ratio: 5.12
• Current Ratio: 2.85
• Quick Ratio: 2.85

Sales & Book Value

• Annual Sales: $88.50 million
• Price / Sales: 3.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.31) per share
• Price / Book: -85.23

Miscellaneous

• Outstanding Shares: 10,550,000
• Free Float: 8,103,000
• Market Cap: $278.73 million
• Optionable: No Data
• Beta: 0.56